Ventilator Associated Pneumonia Multiplex PCR for Anti-Infective Regimens

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCHU de Reims

About this trial

Ventilator-associated pneumonia (VAP) remains one of the main nosocomial infections acquired in the intensive care unit (ICU). VAP is pneumonia occurring 48 hours after intubation. Today, bronchoalveolar lavage (BAL) is used for microbiological diagnosis, with bacterial culture and antibiotic susceptibility results within 48 to 72 hours. Multiplex PCR can detect DNA of a number of bacteriae, as well as the presence of resistance genes. However, its clinical value in the ICU remains to be demonstrated. We think that the use of multiplex PCR with a panel adapted to the microbiology of VAP, could be an interesting method for clinicians in ICU.

Eligibility criteria

Qualifiers

Adult patients, hospitalized in intensive care unit

on mechanical ventilation for at least 48 hours

Suspected VAP

With an indication for bronchoalveolar lavage (BAL)

Disqualifiers

Patients under legal protection or without social security coverage

Pregnant women

Previous episode of VAP during the same hospitalization

Trial design

Treatments tested in this trial

  • Multiplex PCR

Treatment groups

265 Participants
are divided into 2 treatment groups

Sponsors and collaborators